<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885690</url>
  </required_header>
  <id_info>
    <org_study_id>3.1 - 01-25-09</org_study_id>
    <secondary_id>Eudra CT nr: 2008-008366-13</secondary_id>
    <nct_id>NCT00885690</nct_id>
  </id_info>
  <brief_title>Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)</brief_title>
  <acronym>SEROLA</acronym>
  <official_title>A Multicentre Double-blinded Randomized Head-to-head Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg Psychiatric Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malmö University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognition is one of the core symptoms of schizophrenia. This study is a head-to-head trial
      between olanzapine and sertindole with cognition as primary outcome. The design is a 12-week
      double-blinded randomized controlled flexible dose study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to recruitment problems
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CANTAB cognitive test battery</measure>
    <time_frame>Baseline - 6 and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose, lipid profile, HbA1c, body weight, abdominal circumference, blood pressure</measure>
    <time_frame>Baseline - 6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS, CGI, Sf-36 (quality of life), GAF (social function), UKU (side effects), DAI (attitude towards medicine), Beck's insight scale, Specific Level of Functioning (SLOF)</measure>
    <time_frame>Baseline, 6 and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Sertindole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sertindole 16-24 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine 10-20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertindole</intervention_name>
    <description>Sertindole 16-24 mg once daily</description>
    <arm_group_label>Sertindole</arm_group_label>
    <other_name>Serdolect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 10-20 mg</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AnICD-10 schizophrenia diagnosis F20.0-F20.9.

          -  Contraception.

          -  A negative pregnancy test for women.

          -  No known allergy to any of the substances in the study medication

          -  Baseline QTc &lt; 450 milliseconds for men and &lt; 470 milliseconds for women

          -  S-potassium and s-magnesium within normal reference range.

          -  Suboptimally treated on current antipsychotic medication

          -  Stable dosage of antidepressants and mood stabilizers one month before the inclusion

          -  Signed informed consent and power of attorney

        Exclusion Criteria:

          -  Withdrawal of consent

          -  QTc prolongation &gt;500 milliseconds during the study

          -  Patients with known clinical important cardiovascular disease

          -  Significant substance abuse

          -  Earlier partial or non-response in treatment or intolerability to sertindole or
             olanzapine.

          -  Calgary Depression Scale score ≥ 7

          -  Treatment that interferes with the metabolism of sertindole or olanzapine,

          -  Oxazepam, zopiclone or zolpidem treatment the last 48 hours before cognitive testing

          -  Prescription of not-allowed medication, or a change in dosage of antidepressant, or
             mood stabilizers in the study period

          -  Treatment with an anticholinergic after the first three weeks of the study

          -  Somatic illness, as judged by investigator, interfering with cognition

          -  Known risk of narrow angle glaucoma

          -  Treatment with electroconvulsive therapy (ECT) the last three months before inclusion,
             or treatment with ECT in the study period

          -  Treatment with clozapine or depot antipsychotics before inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>René Nielsen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Psychiatric Hospital, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Psychiatric Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitets Allmänna Sjukhuset, Malmø UMAS</name>
      <address>
        <city>Malmø</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Sertindole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

